On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.

On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.